Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma

Status Recruiting

Clinical Trial Summary

This phase II trial studies the side effects and best dose of propranolol when administered concurrently with SOC neoadjuvant CRT in patients with esophageal carcinoma, with a safety lead-in and dose expansion cohort. Patients who are already on β-blockers will receive standard of care CRT and will be considered separately as a single arm prospective cohort

Clinical Trial Description

PRIMARY OBJECTIVE: I. To determine the safety and efficacy of propranolol hydrochloride (propranolol) in combination with standard neoadjuvant/definitive chemoradiation therapy (CRT) for esophageal cancer. SECONDARY OBJECTIVE: I. To estimate overall survival (OS) and pathologic response rate in patients that undergo surgery. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04682158
Study type	Interventional
Source	Roswell Park Cancer Institute
Contact	ASK RPCI
Phone	1-800-767-9355
Email	askroswell@roswellpark.org
Status	Recruiting
Phase	Phase 2
Start date	April 1, 2021
Completion date	April 1, 2027

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04159974` - RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus	Phase 2
Completed	`NCT03015389` - Wide Area Transepithelial Sample Esophageal Biopsy Combined With Computer Assisted 3-Dimensional Tissue Analysis (WATS3D) For the Detection of High Grade Esophageal Dysplasia and Adenocarcinoma
Terminated	`NCT04642690` - Nitrates and IL-8 in Barrett's Esophagus
Withdrawn	`NCT03982173` - Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors	Phase 2
Completed	`NCT02128243` - Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer	Phase 2
Recruiting	`NCT04430738` - Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers	Phase 1/Phase 2
Recruiting	`NCT04114136` - Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies	Phase 2
Terminated	`NCT03223662` - Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy	Phase 2
Recruiting	`NCT05530343` - Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance	N/A
Active, not recruiting	`NCT03539822` - Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies	Phase 1/Phase 2
Recruiting	`NCT05902988` - A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer	Phase 1/Phase 2
Completed	`NCT01970306` - Evaluate Esophageal Reinforcement With ACell MatriStem Surgical Matrix: A Degradable Biologic Scaffold Material	Phase 2
Recruiting	`NCT06071845` - Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples	N/A
Active, not recruiting	`NCT02872116` - Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer	Phase 3
Terminated	`NCT04089904` - Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma	Phase 2
Recruiting	`NCT05177133` - Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)	Phase 2
Recruiting	`NCT02962063` - Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer	Phase 1/Phase 2
Recruiting	`NCT02606396` - Cryotherapy for Malignant Dysphagia in Patients With Advanced Esophageal Cancer	N/A
Completed	`NCT02610764` - Pilot Sudy: Resectable Esophageal Adenocarcinoma and the Relevance of CTC	N/A
Terminated	`NCT00430027` - Preoperative Capecitabine, Oxaliplatin, Cetuximab, and Radiation Therapy for Locally Advanced Esophageal Adenocarcinoma	N/A